Table 2.
HR estimates and 95% CIs comparing treatment arms F and G to the reference arm A in the N9741 trial data based on PFS as a composite endpoint, using three analysis strategies*
| Analysis | HR (95% CI) | ||
|---|---|---|---|
| Composite endpoint |
HRC (95% CI) |
||
| Arm F | 0.68 (0.60 to 0.78) | ||
| Arm G | 0.93 (0.80 to 1.07) | ||
| Univariate |
HR1* (95% CI) |
HR2* (95% CI) |
|
| Arm F | 0.67 (0.59 to 0.77) | 0.66 (0.58 to 0.75) | |
| Arm G | 0.93 (0.80 to 1.08) | 0.90 (0.77 to 1.04) | |
| Semicompeting risks |
HR1 (95% CI) |
HR2 (95% CI) |
HR3 (95% CI) |
| Arm F | 0.49 (0.40 to 0.60) | 0.60 (0.34 to 1.09) | 0.59 (0.48 to 0.72) |
| Arm G | 0.83 (0.66 to 1.04) | 0.82 (0.34 to 1.65) | 0.82 (0.66 to 1.03) |
Treatment arm A (reference arm): 5-FU/LV (5-fluorouracil and leucovorin) with CPT-11 (irinotecan); treatment arm F: 5-FU/LV with OXAL (oxaliplatin); treatment arm G: OXAL with CPT-11. CI = confidence interval; HR = hazard ratio; HR1 = HR for progression in semicompeting risks analysis; HRC = HR for composite endpoint; HR1* = HR for progression in univariate analysis; HR2 = HR for death given that progression has not occurred in semicompeting risks analysis; HR2* = HR for death in univariate analysis; HR3 = HR for death given that progression has occurred in semicompeting risks analysis; PFS = progression-free survival.